Actinogen (ASX:ACW) is progressing development of its novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders.
The company has now been granted an ASX trading halt in relation to a capital raising for a Phase II study in Alzheimer’s dementia.
This will last until the earlier of the announcement being made or the start of trade on Friday, 24th April 2015.
Actinogen’s lead drug candidate Xanamem is being developed as a new therapy for Alzheimer’s disease.
Earlier this month, the company successfully dosed the second cohort of Phase I trial participants with 20mg of Xanamem.
This led to its being granted approval to escalate the dose to 35mg for the final cohort.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.